Combination therapy may improve immune response against advanced prostate cancer

Combining the targeted therapy olaparib with an additional immunotherapy may improve immune response in a subgroup of patients with metastatic castration-resistant prostate cancer who responded poorly to initial treatment, according to a Northwestern Medicine study published in The Journal of Clinical Investigation.

≈